<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk-adapted management of recurrent non-muscle invasive bladder cancer*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk-adapted management of recurrent non-muscle invasive bladder cancer*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Risk-adapted management of recurrent non-muscle invasive bladder cancer*</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Risk stratification at time of disease recurrence<sup>[1-3]</sup></td> <td class="subtitle1">Prior management</td> <td class="subtitle1">Treatment of recurrent disease</td> <td class="subtitle1">Later-line therapy</td> </tr> <tr> <td class="divider_bottom" rowspan="5">Intermediate-risk disease: <ul class="decimal_heading"> <li>LG Ta with recurrence within one year</li> <li>Solitary LG Ta &gt;3 cm</li> <li>Multifocal LG Ta</li> <li>Solitary HG Ta ≤3 cm</li> <li>LG T1</li> </ul> </td> <td rowspan="3">TUR only</td> <td>Surveillance, office tumor fulguration, or TURBT</td> <td>Continue surveillance, office tumor fulguration, or TURBT; or intravesical therapy.</td> </tr> <tr> <td>Intravesical chemotherapy</td> <td>Intravesical BCG.</td> </tr> <tr> <td>Intravesical BCG</td> <td>Intravesical chemotherapy.</td> </tr> <tr> <td>Prior intravesical chemotherapy</td> <td>Intravesical BCG</td> <td class="divider_bottom" rowspan="2">Other intravesical chemotherapy. Evaluate for radical cystectomy if unable to control disease.</td> </tr> <tr class="divider_bottom"> <td>Prior intravesical BCG</td> <td>Intravesical chemotherapy</td> </tr> <tr> <td class="divider_bottom" rowspan="5">High-risk disease: <ul class="decimal_heading"> <li>HG Ta &gt;3 cm</li> <li>Multifocal or recurrent HG Ta</li> <li>HG T1</li> <li>CIS</li> </ul> </td> <td>TUR only</td> <td>Intravesical BCG</td> <td>Refer to treatment approach for high-risk disease, prior BCG therapy.</td> </tr> <tr> <td>Prior intravesical chemotherapy</td> <td>Intravesical BCG</td> <td rowspan="2"> <p>If recurrence is more than 6 months (Ta/T1) or 12 months (CIS) after the last BCG dose, retreat as a late relapse with a second cycle of intravesical BCG. If disease does not respond, radical cystectomy is preferred over a third cycle of intravesical BCG.</p> Otherwise, refer to treatment approach for high-risk disease, prior BCG therapy: BCG-unresponsive disease.</td> </tr> <tr> <td>Prior BCG therapy: BCG-exposed disease<sup>¶</sup></td> <td>Intravesical BCG</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Prior BCG therapy: BCG-unresponsive disease<sup>Δ</sup></td> <td colspan="2">Radical cystectomy<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td> <p>For patients who are ineligible for or decline radical cystectomy, options include intravesical therapy<sup>§</sup> or systemic pembrolizumab (for CIS with or without Ta/T1 disease)</p> </td> <td>Radical cystectomy.</td> </tr> <tr> <td rowspan="2">Very high-risk disease: <ul class="decimal_heading"> <li>HG T1 with any of the following: <ul> <li>Multiple and ≥3 cm tumors</li> <li>Presence of concurrent CIS (in the bladder or prostatic urethra)</li> <li>Presence of LVI</li> <li>Variant histology (eg, micropapillary, plasmacytoid, sarcomatoid, neuroendocrine)</li> </ul> </li> </ul> </td> <td colspan="3">Radical cystectomy (regardless of prior therapy)</td> </tr> <tr> <td>Patient is not eligible for or declined radical cystectomy</td> <td colspan="2">Refer to treatment approach for high-risk disease.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>LG: low grade; 
        TUR: transurethral resection;
        TURBT: transurethral resection of bladder tumor; 
        BCG: Bacillus Calmette-Guerin; 
        HG: high grade; 
        CIS: carcinoma in situ; 
        LVI: lymphovascular invasion.</p>
<p>* Non-muscle invasive bladder cancer is a heterogeneous group of tumors that can be papillary tumors (Ta [non-invasive] or T1 [lamina propria invasive]) and/or CIS. Ta tumors can be LG or HG. T1 tumors are almost always HG. Clinical trial enrollment is encouraged, where available.</p>
<p>¶ BCG-exposed is defined as high-risk non-muscle invasive bladder cancer treated with a single round of induction BCG without maintenance therapy, and those who receive maintenance BCG but relapse with high-grade disease more than 12 months and less than 24 months after the last dose of BCG.</p>
<p class="extra_spacing_top">Δ BCG-unresponsive is defined as one of the following, in the absence of urothelial carcinoma of the prostatic urethra or upper tract:</p>
<ul>
<li>Persistent or recurrent <strong>high-grade</strong> Ta/Tis urothelial carcinoma of the bladder after completion of at least induction (≥5 doses) and one round of maintenance (or second induction; ≥2 doses) intravesical BCG.</li>
<li>Persistent or recurrent <strong>high-grade</strong> T1 bladder cancer after induction BCG (≥5 doses) without further maintenance therapy.</li>
<li>Initial complete response (no disease six months after diagnosis) followed by subsequent <strong>high-grade</strong> recurrence within 6 (Ta/T1) or 12 months (CIS with or without Ta/T1) after the last BCG dose.</li>
</ul>
<p class="extra_spacing">◊ For BCG-unresponsive disease, radical cystectomy is the most definitive therapy with the lowest risk of progression, but there is risk of overtreatment.</p>
    
    § Preferred options for intravesical therapy for BCG-unresponsive disease include sequential gemcitabine and docetaxel, and nadofaragene firadenovec (for CIS with or without Ta/T1 disease). Single-agent intravesical gemcitabine, docetaxel, or mitomycin are alternatives for those who are unable to receive the preferred agents.</div><div class="graphic_reference">References:
    <ol>
<li>Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016; 196:1021.
        </li>
<li>Kim SH, Lerner SP. Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors. J Clin Oncol 2023; 41:163.
        </li>
<li>Bhindi B, Kool R, Kulkarni GS, et al. Canadian Urological Association guideline
        on the management of non-muscle-invasive bladder cancer. Can Urol Assoc J 2021; 15:E424.</li>
</ol></div><div id="graphicVersion">Graphic 108293 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
